Royalty Report: Drugs, Biotechnology, Cancer – Collection: 28542

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 15

Primary Industries

  • Drugs
  • Biotechnology
  • Cancer
  • Therapeutic
  • Delivery
  • Vaccine
  • Diagnostic
  • Disease
  • Food
  • Beverages
  • Nutraceutical
  • Diagnostic Substances
  • cardiac
  • Immune
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28542

License Grant
Licensor grants to Licensee an exclusive right and license, with a right to sublicense to Affiliates and others in accordance with the provisions hereof, in the Territory under the Licensed Patent and Licensed Information to make, have made, use, import, sell, have sold and offer to sell Licensed Products in the Field.
License Property
Licensor has rights to technology relating to cochleates, liposomes and proteoliposomes which will elicit an antigen specific immune response in humans and which are used in the formulation of human vaccines and has rights to patent applications and patents related to said technology.

Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.

Field of Use
Field means vaccines designed to induce (not limited to type of immune modulation) an antigen(s) specific immune response in humans; including vaccines to prevent or treat allergies (Type I hypersensitivity reaction), but not including vaccines to treat autoimmunity nor vaccines made from patient specific antigen(s) for patient specific therapy.

IPSCIO Record ID: 27064

License Grant
The University hereby grants an exclusive license to make, have made, use, import, offer for sale, and sell the Licensed Products in the Field.
License Property
IL-1b shall mean human Interleukin-1 beta protein, fragments of human Interleukin 1-beta protein, and mutant forms of human Interleukin 1-beta protein.

Patents means patent application serial number 09/168910 entitled Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects.

Field of Use
Field shall mean, and shall be strictly limited to, the development, manufacture, importation, offer for sale, and sale of intra- nasally administered vaccines or vaccine adjuvants formulated with IL-lb for prophylaxis and/or therapy of all human diseases.

IPSCIO Record ID: 5541

License Grant
Licensor has grants an exclusive worldwide sublicense to exploit the technology for all opportunities in the processed food and beverage industry for both human and animal consumption.  Both parties are U.S. corporations.  The grant includes the rights to use registered trademark Bioral in connection with the creation of consumable products. Licensee is wholly owned subsidiary of Licensor.
License Property
The technology involves cochleates, cochleate derivatives, and proteoliposomes, and nano-encapsulation.  Cochleate delivery vehicles represent a new technology platform for oral and systemic delivery of clinically important drugs that possess poor bioavailability.

Cochleate delivery vehicles wrap-up or encapsulate the drug, rather than chemically bond with the included drug.  A few of the US patents include: 1) Liposome Methods and Composition 4,663,161 2) Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles 4,871,488  Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same 3. Stabilizing And Delivery Means of Biological Molecules 5,643,574.  Exhibit has excellent description of technology.  The exhibit does not explain, but the original licensor is the University of Medicine and Dentistry of New Jersey who granted an exclusive worldwide license to develop the cochleate technology and in some cases co-owns the patents with the corporation.

Trademark 'Bioral'

Field of Use
Field shall mean delivery of Consumable Products to all living systems for processed foods applications for both human and Animal consumption.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 280951

License Grant
The Canadian University grants to the Canadian Licensee an exclusive license, together with the right to grant sublicenses, in the territory for the field of use to practice the Patent Rights and otherwise use the Licensed Technology and to make, develop, use, import, offer to sell, sell, market and distribute and have made, developed, used, imported, offered to sell, sold, marketed and distributed Licensed Products.
License Property
Licensor has certain compositions and methods to elicit Thl immune response for use in vaccines.

BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.

Field of Use
The Field of use means any and all uses of the licensed technology in liposomal cancer vaccines.

IPSCIO Record ID: 29101

License Grant
A University hereby grants to the Licensee an exclusive License under Patent Rights, including the right to grant sublicenses.
License Property
The licensed field is for the diagnosis, treatment and prevention of autoimmune disease and includes inventions disclosed in Disclosure Docket No. SD1993-268:  â€œMethod and Reagents for the Treatment of Rheumatoid Arthritis'/ 'Vaccine Compositions and Methods Useful in Inducing Immune Protection Against Arthritogenic Peptides Involved in the Pathogenesis of Rheumatoid Arthritis'; SD2000-133, 'Pan HLA DR Binding Heat Shock Protein Peptides as Immunomodulatory Tools'; SD2001-901, 'Pan HLA DR Binding Heat Shock Proteins as Immunomodulatory Tools'; SD2002-051 'Methods of Epitope-Specific and Cytokine/Anticytokine Immunotherapy for Modulation of Pathogenic Immune Responses in Mediated Diseases'; and SD2006-256 'Methods and Formulations for Epitope Specific Immunotherapy.'
Field of Use
'Field' means diagnosis, treatment and prevention of autoimmune disease.

IPSCIO Record ID: 203340

License Grant
Licensor grants to the Italian Licensee the sole and exclusive license under the Patents and the Know-How to use, offer for sale, sell, develop, manufacture, and have manufactured the Products in the Field in the Territory, with the right to grant sublicenses relating only to Products in the Field in the Territory.
License Property
The patents and know-how are for Liposome Methods and Composition, Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles, Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same,  Stabilizing And Delivery Means of Biological Molecules, Protein-Lipid Vesicles and Autogenous Vaccine Comprising The Same, Nanocochleate Formulations, Process of Preparation and Method of Delivery of Pharmaceutical Agents, Cochleates From Purified Soy Phosphatidylserine, Geodate Delivery Vehicles, Rigid Liposomal Compositions, Cochleate Preparations of Fragile Nutrients, Antisense Cochleates, Cochleates Including Aggregation Inhibitors, Novel Encochleation Methods, Cochleates and Methods of Use, Replacement Enzyme Cochleates, Apoprotein Cochleate Compositions, Cochleate Compositions Directed Against Expression of Proteins, and, Novel Encochleation Methods, Cochleates and Methods of Use.

Products means any product in finished pharmaceutical form for use and sale in the Field containing the Compounds formulated with and incorporating the Patents and Know-How and covered by a Valid  Claim.

Field of Use
Field means solely for use of the Products in oncology, cardiovascular and immunology pharmaceuticals.

It is Licensee's intention to use Licensor's licensed, Bioral(TM) nanocochleate drug delivery technology to provide for oral delivery of pharmaceutical products incorporating these compounds.

IPSCIO Record ID: 7755

License Grant
The Licensor hereby grants to the Licensee an exclusive license in the Territory with the right to sublicense under the Patent Rights to research, develop, use, manufacture, have manufactured, sell, offer to sell or have sold TranzFect as it relates to use with Substance in the Field; and Licensed Product. Included is the right to Sublicense.
License Property
The Licensor has rights to Patents Rights collectively referred to as Poloxamer Intellectual Property.

The term PSMA shall mean all compositions and uses of, collectively: molecules that elicit an immune response specific for prostate specific membrane antigen.

The term TranzFect shall mean any polyoxypropylene/polyoxyethylene copolymer compound or compositions or preparations of such compounds claimed in or covered by CytRx Poloxamer Intellectual Property that may be added to Substance to enhance performance of such Substance relative to use of the Substance without Tranzfect.

US PATENT 5,554,372  Methods and vaccines comprising surface-active copolymers
US PATENT 6,086,899  Ethylene oxide-propylene oxide copolymer
US PATENT 5,824,322  Compositions and methods for growth promotion

Field of Use
Field shall mean the use of Licensor Poloxamer Intellectual Property limited to protein, DNA or viral vaccines based on Licensee for use in any human therapeutic and/or prophylactic medical use.

Licensee will enter research and development activities related to the use of Transfect in the Field, to develop and commercialize a Licensed Product on a commercially reasonable basis.

IPSCIO Record ID: 7076

License Grant
Licensor hereby grants to Licensee an exclusive license throughout the Territory, with the right to grant sublicenses to make, use or sell Licensed Products in the Field.
License Property
Licensed Product shall mean a Product in the form of (a) antifungal preparations (including Amphotericin B preparations) for mucosal surface application for the indications of chronic sinusitis and asthma; and (b) transmucosal vaccine preparations for the indications of chronic sinusitis and asthma.

Antifungal Products shall mean any and all products covered by the patent rights licensed to Licensee by MAYO.

Technology refers to encochleated formulation of amphotericin B for topical treatments for CRS and asthma.

Licensed Patents

Docket No./Title/

  
Appln No./Patent No.
Country

BSZ-005: Liposome Methods and Composition US 4,663,161

BSZ-005DV: Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles
US 4,871,488

BSZ-006: Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same US 5,643,574

BSZ-006CP: Stabilizing Delivery Means of Biological MoleculesInt’I (PC) US94/10913

Field of Use
Field shall mean the field of any topical antifungal (including Amphotericin B) for mucosal surface application for the indications of chronic sinusitis and asthma covered by patents licensed to Licensee by the Mayo Clinic (MAYO), and transmucosal vaccine applications covered by a patent held by MAYO for the indications of chronic sinusitis and asthma.

IPSCIO Record ID: 227255

License Grant
The Licensor grants to the Licensee an exclusive license under the Licensed Patent Technology, with the right to grant and authorize sublicenses, to make, have made, import, use, offer for sale and sell Licensed Products throughout the Licensed Territory in the Licensed Field Of Use for the term of this Agreement. Licensee shall have the right to extend this license to any Affiliate(s) of its choice subject to Licensor’s approval that each such extension properly references this Agreement, including those rights retained by Licensor hereunder, and is consistent with the relevant provisions hereof that apply to sublicenses, such approval to be provided by Licensor.
License Property
Licensed Patent Technology means all of Licensor’s rights in and to (a) U.S. Patent Nos. 5,910,306 (entitled 'Transdermal Delivery System for Antigen') and 5,980,898 (entitled 'Adjuvant for Transcutaneous Immunization'), including any extensions, reissues and reexaminations thereof, (b) any and all patents and patent applications identified hereto and made a part hereof, (c) any and all Subject Inventions that arose under the First MTPPI CRADA prior to the effective date of the Second MTPPI CRADA, and (d) any Improvements of the foregoing. Licensed Patent Technology shall include any and all divisions, continuations, continuations-in-part, and substitutions related to the patents and patent applications referenced in this agreement; all foreign patent applications corresponding to the foregoing applications; and all U.S. and foreign patents issuing on any of the foregoing applications, including extensions, reissues, and reexaminations.

Licensed Product(s) means any and all products which either fall within the scope of one or more Valid Claims of the Licensed Patent Technology, or are produced by the practice of, or are made for use in, a method that is within the scope of one or more Valid Claims of the Licensed Patent Technology, in the country of manufacture or sale by Licensee or its Affiliate(s).

Field of Use
Licensed Field Of Use means any and all human and nonhuman applications or uses for the Licensed Patent Technology.
Licensed rights for transcutaneous vaccine system.

IPSCIO Record ID: 28637

License Grant
Hospital hereby grants to Company the right to obtain a worldwide license to manufacture, use sell or lease products and/or processes incorporated in the Inventions. The license contemplated by this this Agreement will be exclusive, royalty-bearing, subject to Due Diligence requirements and subject to a License Issue Fee upon execution.
License Property
Dr. Gerald Pier is named as inventor on United States Patent 4,578,458 (and related foreign patents) entitled Muciod Exopolysaccharide Vaccine Against Pseduomanas Aeruginosa issued March 25, 1986, and United States Patent 5, 502,039 entitled o-Derivatized Alginic Acid Antigens issued March 26, 1996, both are described in this Agreement. (Inventions).
Field of Use
The rights granted apply to license the Inventions for therapeutic purposes only.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The original agreement Field means any and all uses.  The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 249713

License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens:
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.

In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
• Any and all Antigens expressed in Lung Cancer

License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.

The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.

Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.

Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.

IPSCIO Record ID: 4396

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive, royalty-bearing sub-license under the Licensed Patents, including the right to grant further sublicenses solely to make, have made, use, import, sell, or have sold Licensed Products in the Territory under the Field of Use.
License Property
GRNVAC means the technology acquired by the Licensee under the Asset Contribution Agreement pertaining to the presentation of one or more antigens to the immune system using patient monocyte-derived (VAC-1) or dendritic cells or human embryonic stem cell-derived or induced pluripotent stem cell-derived antigen presenting cells (VAC-2).

018/062C
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
US
09/438,486
12-Nov-99
6,927,285
018/181C
Telomerase
US
09/843,676
26-Apr-01
7,056,513
018/210C
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
US
09/721,506
22-Nov-00
7,262,288
018/213C
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
US
10/044,692
11-Jan-02
7,560,437
018/221P
Human Telomerase Reverse Transcriptase Polypeptides
US
10/877,124
24-Nov-09
7,622,549
018/224C
Immunogenic Composition
US
11/894,643
20-Aug-07

Field of Use
Licensee has acquired Licensor’s technology directly related to the research, development and commercialization of products based on primate pluripotent embryonic stem cells.

Field of Use means use of telomerase as an antigen in an immunotherapeutic product  for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.

IPSCIO Record ID: 28678

License Grant
The Canadian University hereby grants the Canadian Licensee an exclusive, royalty-bearing license in the Territory to practice the Licensed Technology and to make, develop, use, import, offer to sell, sell, market and distribute and have made, developed, used, imported, offered to sell, sold, marketed and distributed Licensed Product(s), until the end of the term of the last registered patent, at which time the license shall become a perpetual, fully-paid up, royalty-free license, unless this Agreement is sooner terminated according to the terms defined in this Agreement.
License Property
Licensee shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted in this Agreement but only with the prior written consent of University.

The University is the owner of certain Patent Rights (as later defined in this Agreement) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed: June 7, 1995).

Patent Rights means all of the following UA intellectual property:
  (a)   the US Patent application No. 08/480,499 A Method for Eliciting a Thl Specific Immune Response (filed: June 7, 1995);

  (b)   the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), a continuation-in-part of 1.6 (a) and later issued as US Patent No. 6,168,804 (issued: January 2, 2001);

  (c)   the US Patent application No. 09/668,825 A Method for Eliciting a Thl Specific Immune Response, a divisional application of 1.6 (b) (filed: September 22, 2000);

  (d)   any US divisional patent applications covering the invention disclosed in the patent application 1.6 (b) above and the resulting patents;
  (e)  any US continuation-in-part application, and the resulting patents, which are directed to the invention disclosed in the patent applications described in sections 1.6 (b), (c) and (d) above;
  (f)  any Canadian and foreign patent applications, and the resulting patents, which are based on the invention disclosed in the patent applications described in sections 1.6(e) above; and
  (g)  any reissues, extensions and divisions of Canadian and foreign patents described in sections 1.6 (b), (c), (d), (e) and (f) above.

Field of Use
Field of Use means any and all uses of microsphere formulations that infringe one or more claims contained in the Patent Rights for the treatment of infectious disease and cancer caused by chronic viral infection, including but not limited to hepatoma. (For greater certainty, the Field of Use does not include any use of the Patent Rights in liposomal cancer vaccines.)
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.